ATE554784T1 - Hochaffiner ligand für p75 neurotrophin-rezeptor - Google Patents
Hochaffiner ligand für p75 neurotrophin-rezeptorInfo
- Publication number
- ATE554784T1 ATE554784T1 AT02729305T AT02729305T ATE554784T1 AT E554784 T1 ATE554784 T1 AT E554784T1 AT 02729305 T AT02729305 T AT 02729305T AT 02729305 T AT02729305 T AT 02729305T AT E554784 T1 ATE554784 T1 AT E554784T1
- Authority
- AT
- Austria
- Prior art keywords
- proneurotrophin
- protein
- methods
- mammal
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29382301P | 2001-05-25 | 2001-05-25 | |
US30551001P | 2001-07-13 | 2001-07-13 | |
PCT/US2002/016540 WO2002096356A2 (en) | 2001-05-25 | 2002-05-24 | HIGH AFFINITY LIGAND FOR p75 NEUROTROPHIN RECEPTOR |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE554784T1 true ATE554784T1 (de) | 2012-05-15 |
Family
ID=26968166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02729305T ATE554784T1 (de) | 2001-05-25 | 2002-05-24 | Hochaffiner ligand für p75 neurotrophin-rezeptor |
Country Status (7)
Country | Link |
---|---|
US (2) | US7507799B2 (de) |
EP (1) | EP1575477B1 (de) |
AT (1) | ATE554784T1 (de) |
AU (1) | AU2002259305A1 (de) |
CA (1) | CA2447986A1 (de) |
DK (1) | DK1575477T3 (de) |
WO (1) | WO2002096356A2 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002259305A1 (en) * | 2001-05-25 | 2002-12-09 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
US8066997B2 (en) | 2002-12-20 | 2011-11-29 | Anders Nykjaer | Modulation of activity of neurotrophins |
DE10317369A1 (de) * | 2003-04-15 | 2004-11-11 | Scil Proteins Gmbh | proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen |
EP1500399A1 (de) * | 2003-07-24 | 2005-01-26 | Institut Pasteur | Aktive und passive Immunisierung gegen pro-apoptotischen Neurotrophinen zur Behandlung oder Vorbeugung von neurologischen Krankheiten |
CN1897977A (zh) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
EP1682170A2 (de) * | 2003-11-07 | 2006-07-26 | Lay Line Genomics SpA | Zusammensetzungen zur prävention von neurodegenerativen prozessen und testverfahren dafür |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
ITRM20050045A1 (it) * | 2005-02-02 | 2006-08-03 | Consiglio Nazionale Ricerche | Proteina isolata da eisenia foetida simile all'ngf umano e usi relativi. |
ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
US20080050776A1 (en) * | 2006-05-26 | 2008-02-28 | Kenneth Neet | Stable mutated pro nerve growth factors |
HUE048781T2 (hu) | 2006-12-21 | 2020-08-28 | H Lundbeck As | Proneurotrofinok aktivitásának modulációja |
JP5871249B2 (ja) * | 2010-05-31 | 2016-03-01 | 国立研究開発法人産業技術総合研究所 | 成長因子のプロペプチド |
US20130115222A1 (en) * | 2010-06-15 | 2013-05-09 | Cornell University | Methods of limiting microvascular damage following acute myocardial ischemia |
US20130336988A1 (en) * | 2010-11-17 | 2013-12-19 | New York University | Methods for treating early stage or mild neurological disorders |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
RU2486918C1 (ru) * | 2011-10-25 | 2013-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций |
MX353074B (es) | 2011-12-19 | 2017-12-19 | Wacker Chemie Ag | Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la produccion de factor de crecimiento del nervio beta. |
US20140256639A1 (en) * | 2013-02-14 | 2014-09-11 | The Regents Of The University Of California | Peptoid neutralizing agents |
US20160220639A1 (en) * | 2013-09-11 | 2016-08-04 | New York University | Methods and compositions for treating bone diseases |
CN104774264B (zh) * | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
US10500273B2 (en) | 2015-03-02 | 2019-12-10 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an IL-33 antagonist |
US20210079050A1 (en) * | 2018-02-20 | 2021-03-18 | Carmel Haifa University Economic Corporation Ltd. | Compositions and methods for delivery and expression of small inhibitory peptides and use thereof |
IT202000007720A1 (it) * | 2020-04-10 | 2021-10-10 | Alessandra Marconi | Peptidi e loro usi |
IT202000032423A1 (it) * | 2020-12-24 | 2022-06-24 | Univ Degli Studi Di Trieste | Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita |
WO2022226170A1 (en) * | 2021-04-22 | 2022-10-27 | Cornell University | The immunomodulatory ligand b7-1 mediates synaptic remodeling by p75ntr |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169762A (en) * | 1983-03-03 | 1992-12-08 | Genentech, Inc. | Human nerve growth factor by recombinant technology |
US5169764A (en) * | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
US5958875A (en) | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
JPH10212241A (ja) * | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Bdnfを安定に含有する製剤 |
US5840736A (en) * | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
WO2000024415A2 (en) | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
US6960440B2 (en) * | 1999-06-07 | 2005-11-01 | The Trustes of Columbia University in the City of New York | Methods for screening for apoptosis modulators using NADE, p75NTR-associated cell death executor |
CA2397670C (en) | 2000-01-18 | 2010-06-08 | Mcgill University | .beta.-turn peptidomimetic cyclic compounds |
GB0007918D0 (en) | 2000-03-31 | 2000-05-17 | Npower | Passive valve assembly |
AU2002259305A1 (en) | 2001-05-25 | 2002-12-09 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
-
2002
- 2002-05-24 AU AU2002259305A patent/AU2002259305A1/en not_active Abandoned
- 2002-05-24 DK DK02729305.9T patent/DK1575477T3/da active
- 2002-05-24 US US10/155,886 patent/US7507799B2/en not_active Expired - Fee Related
- 2002-05-24 AT AT02729305T patent/ATE554784T1/de active
- 2002-05-24 EP EP02729305A patent/EP1575477B1/de not_active Expired - Lifetime
- 2002-05-24 CA CA002447986A patent/CA2447986A1/en not_active Abandoned
- 2002-05-24 WO PCT/US2002/016540 patent/WO2002096356A2/en not_active Application Discontinuation
-
2007
- 2007-07-27 US US11/881,763 patent/US8034347B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1575477A2 (de) | 2005-09-21 |
US20080025978A1 (en) | 2008-01-31 |
DK1575477T3 (da) | 2012-07-23 |
WO2002096356A3 (en) | 2006-05-18 |
CA2447986A1 (en) | 2002-12-05 |
US8034347B2 (en) | 2011-10-11 |
EP1575477A4 (de) | 2006-11-08 |
AU2002259305A1 (en) | 2002-12-09 |
AU2002259305A8 (en) | 2006-11-02 |
EP1575477B1 (de) | 2012-04-25 |
WO2002096356A2 (en) | 2002-12-05 |
US20030087804A1 (en) | 2003-05-08 |
US7507799B2 (en) | 2009-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE554784T1 (de) | Hochaffiner ligand für p75 neurotrophin-rezeptor | |
ME00356B (me) | Novi peptidi koji se vezuju za receptor eritropoietina | |
TW200611911A (en) | Antibodies to erythropoietin receptor and uses thereof | |
WO2005058815A3 (en) | Ip-10 antibodies and their uses | |
NO20055847L (no) | Nye peptider som binder til erytiupoietinreseptoren | |
NO20082559L (no) | Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer | |
DE60131146D1 (de) | Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren | |
WO1999006545A3 (en) | Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation | |
TW200621721A (en) | Methods of preparing indazole compounds | |
WO2003076592A3 (en) | Novel method for delivery and intracellular synthesis of sirna molecules | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
PT907731E (pt) | Receptores gaba[b] metabotropicos, ligandos especificos dos receptores e suas utilizacoes | |
EA200700403A1 (ru) | ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ | |
MXPA02008239A (es) | Gen humano de la esquizofrenia. | |
MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. | |
DE60135158D1 (de) | Antagonisten des ige-rezeptors | |
DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
ATE247130T1 (de) | Inhibitoren für den urokinaserezeptor | |
DK1051491T3 (da) | Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf | |
CA2380216A1 (en) | Use of interleukin-18 inhibitors to inhibit tumor metastasis | |
DE60130565D1 (de) | Pde8a und seine verwendung | |
EA200700990A1 (ru) | Новые пептиды, которые связывают рецептор эритропоэтина | |
ATE442444T1 (de) | Glykosylphosphatidylinositolhaltige polypeptide | |
ATE420162T1 (de) | Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen | |
DE60020970D1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen |